Book contents
- Handbook of Drugs in Intensive Care
- Handbook of Drugs in Intensive Care
- Copyright page
- Dedication
- Contents
- Introduction
- How to Use This Book
- Common Abbreviations
- Acknowledgements
- Drugs: An A–Z Guide
- Chapter A
- Chapter B
- Chapter C
- Chapter D
- Chapter E
- Chapter F
- Chapter G
- Chapter H
- Chapter I
- Chapter K
- Chapter L
- Chapter M
- Chapter N
- Chapter O
- Chapter P
- Chapter Q
- Chapter R
- Chapter S
- Chapter T
- Chapter V
- Chapter Z
- Short Notes
- Appendices
- Drug Index
Chapter O
from Drugs: An A–Z Guide
- Handbook of Drugs in Intensive Care
- Handbook of Drugs in Intensive Care
- Copyright page
- Dedication
- Contents
- Introduction
- How to Use This Book
- Common Abbreviations
- Acknowledgements
- Drugs: An A–Z Guide
- Chapter A
- Chapter B
- Chapter C
- Chapter D
- Chapter E
- Chapter F
- Chapter G
- Chapter H
- Chapter I
- Chapter K
- Chapter L
- Chapter M
- Chapter N
- Chapter O
- Chapter P
- Chapter Q
- Chapter R
- Chapter S
- Chapter T
- Chapter V
- Chapter Z
- Short Notes
- Appendices
- Drug Index
Summary
Octreotide is an analogue of somatostatin. It is used to provide relief from symptoms associated with carcinoid tumours and acromegaly. It may also be used for the prevention of complications following pancreatic surgery. For patients undergoing pancreatic surgery, the peri- and post-operative administration of octreotide reduces the incidence of typical post-operative complications (e.g. pancreatic fistula, abscess and subsequent sepsis, post-operative acute pancreatitis). Octreotide exerts an inhibiting effect on gallbladder motility, bile acid secretion and bile flow, and there is an acknowledged association with the development of gallstones in prolonged usage.
- Type
- Chapter
- Information
- Handbook of Drugs in Intensive CareAn A-Z Guide, pp. 227 - 235Publisher: Cambridge University PressPrint publication year: 2025